A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Phase 2 Recruiting 147 enrolled The First Affiliated Hospital of Zhengzhou University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to observe and evaluate the efficacy and safety of multiple drug combinations in the treatment of advanced esophageal squamous cell carcinoma.

Timeline

Start: 2019-12-05
Primary completion: 2021-06-20
Completion: 2025-12-30

Publications

Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, Luo Z, Xia J, Zhou Y, Xu M, Liu E, Jiang G, Li S, Zhao F, Ma C, Ma C, Hou Z, Li J, Wang J, Wang F. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):245-253. doi: 10.1016/S2468-1253(21)00378-2. Epub 2022 Jan 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adebrelimab	Monoclonal antibody	1200 mg	—
Subject	Camrelizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Rivoceranib	Small molecule	250 mg	Oral
Subject	SHR-A2009	Other / unclassified	8 mg/kg	Intravenous

A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Summary

Timeline

Publications

Drugs

Indications